Renoprotection with Semaglutide and Liraglutide:Direct or Indirect Effects?
Johannes F.E. Mann(Katholische Stiftungshochschule München), Vlado Perkovic(University of Copenhagen), Benjamin Ole Wolthers(Novo Nordisk (Denmark)), Lawrence A. Leiter(St. Michael's Hospital), Soren Rasmussen, Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Tina Vilsbøll(University of Copenhagen), Thomas Idorn(University of Copenhagen), John B. Buse(Unknown)
Research at the University of Copenhagen (University of Copenhagen)
January 1, 2019
Cited by 0
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2018|3.5k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k